Search

Case report of a patient with hypercalcemia and suspected parathyroid adenoma. Because of a previous strumectomy a precise preoperative localization of the suspected parathyroid adenoma was demanded. Tc-99m-tetrofosmin scintigraphy in double phase technique failed to detect a parathyroid adenoma by failing to show a region of increased focal uptake with delayed washout in relation to the thyroid gland. Only comparison of the Tc-99m-tetrofosmin images with a Tc-99m-pertechnetate scan revealed a right caudal parathyroid adenoma. A double phase Tc-99m-MIBI study of the same patient was able to localize this parathyroid adenoma without the need of a corresponding Tc-99m-pertechnetate scintigraphy due to a differential washout with persistent focal uptake in the parathyroid adenoma and a progressively decreasing uptake in the thyroid tissue. This case indicates that Tc-99m-tetrofosmin is a suitable agent for parathyroid imaging only if used together with Tc-99m-pertechnetate but it seems to lack the differential washout characteritics of Tc-99m-MIBI according parathyroid gland and thyroid gland.

The performance of a modified Multispect 2 gamma camera, which was supplied with two pairs of collimators constructed for imaging positron emitters was tested. The measurements involved the determination of sensitivity and of spatial resolution. The septal penetration was calculated approximately using two different methods. The spatial resolution determined by FWHM as measured by planar imaging in water at 10 cm distance from the collimator was evaluated as 14.0 mm with collimator 511-A and 12.5 mm with collimator 511-B. Using a Gaussian fit of the line-spread function septal penetrations of 12% with collimator 511-A and of 36% with collimator 511-B were calculated. The absolute system sensitivity measured with 18F was 66 cpm with collimator 511-A and 98.7 cpm/37 kBq with collimator 511-B. The high sensitivity with collimator 511-B may be explained, at least partially, by the high septal penetration.

Although the radiopharmaceuticals used for bone scintigraphy are of very high quality, the search for an "ideal" agent continues. To optimise the detectability of bone lesions, we analysed 244 different 99mTc-labeled phosphonates in animal experiments. In osteosarcoma-carrying rats 99mTc-labeled 1-Hydroxy-3-methyl-phosphinic-1, 1-propanediphosphonic acid (HMPD) was shown to produce the best lesion/normal bone ratio. 99mTc-MDP was used as reference. The ratio was found to be 1.28 for 99mTc-HMPD. The transferability of our results in animals to the situation in man was studied in 10 patients with bone metastases. There was for 99mTc-HMPD an improvement of the lesion/normal bone ratio by more than 60% but also an additional reduction of the soft tissue contrast by about 40%. 15% of the metastases were detected by scintigraphy using 99mTc-HMPD only and not with 99mTc-MDP. The new agent should make possible a better and earlier discrimination of bone lesions in the scintigram.